SS
TRVI icon

Steve Schonfeld’s Trevi Therapeutics TRVI Stock Holding History

Steve Schonfeld’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
+75,970
New +$1.1M 0.01% 1269
2020
Q2 		– Sell
-59,029
Closed -$194K – 1557
2020
Q1 		$194K Sell
59,029
-109,339
-65% -$497K 0.01% 919
2019
Q4 		$632K Sell
168,368
-442
-0.3% -$1.66K 0.02% 657
2019
Q3 		$760K Sell
168,810
-65,632
-28% -$357K 0.02% 537
2019
Q2 		$1.76M Buy
+234,442
New +$2.02M 0.06% 314

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Steve Schonfeld's TRVI Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 75,970 shares worth $1.42M. The stake represents 0.01% of the portfolio and ranks #1269 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in TRVI as recently as Q1 2020.

Steve Schonfeld first reported a position in TRVI in Q2 2019 and has held it in 5 quarters since. The position peaked at $1.76M in Q2 2019. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Steve Schonfeld held 75,970 shares of Trevi Therapeutics worth $1.42M as of Q2 2026.
  • Trevi Therapeutics was a new Steve Schonfeld position in Q2 2026.
  • Trevi Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1269 holding.
  • Steve Schonfeld first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 5 quarters since.
  • Steve Schonfeld's Trevi Therapeutics position peaked at $1.76M in Q2 2019.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.